• Non ci sono risultati.

References Experimental Section Introduction to Experimental Section Introduction Preface INDEX

N/A
N/A
Info
Scarica
Protected

Academic year: 2021

Condividi "References Experimental Section Introduction to Experimental Section Introduction Preface INDEX"

Copied!
1
0
0

Caricamento.... (Visualizza il testo completo ora)

Scarica adesso ( 1 pagine )

Testo completo

(1)

INDEX

Page

Preface

……… 1

Introduction

………..…. 5

Tyrosine Kinase Receptors (RTKs)……… 5

Design of Tyrosine Kinase Inhibitors………... 7

Indirect and Direct Targeting of Angiogenesis Pathways……… 10

Vascular Endothelial Growth Factor and Receptors VEGF/VEGFR… 11 VEGFR signalling………. 13

VEGF/VEGFR in angiogenesis……….. 15

Anti-VEGFR Agents………. 16

Monoclonal Antibody……… 17

Small molecules TK Inhibitors……… 18

Introduction to Experimental Section

………. 22

VEGFR-2 small molecules Inhibitors………... 22

Anthranilamides……… 23

Pyrimidine Derivatives……….. 25

New Benzothiopyrano and Pyridothiopyrano Pyrimidines……….. 31

Chemical synthesis of the 2-aryl substituted benzothiopyrano-pyrimidines……… 37

Chemical synthesis of the 2-aryl substituted pyridothiopyrano-pyrimidines……... 40

Experimental Section

……….. 44

Riferimenti

Scarica adesso ( PDF - 1 pagine - 18.68 KB )

Documenti correlati

COMPARISON OF TWO WAYS OF ADMINISTRATION OF GROWTH FACTORS (bFGF AND RGTA) TO IMPROVE LATISSIMUS DORSI MUSCLE FLAP VASCULARIZATION AND TROPHICITY

We showed in a previous study that local administration of bFGF (basic Fibroblast Growth Factor), VEGF (vascular endothelial growth factor) and RGTA (regenerating agent), at

Fukuoka, “Molecular target-based cancer therapy: tyrosine kinase inhibitors”, International Journal of Clinical Oncology 2003, 8, 207- 211

Gingrich, “Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti- Angiogenic Agents in Cancer Therapy”, Current Medicinal

A Fibrillar Biodegradable Scaffold for Blood Vessels Tissue Engineering

The glycosaminoglycan heparin is able to bind several growth factors like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and, when grafted

Angiogenesis and angioregression gene expression analyses in swine corpus luteum

Among the molecules involved in the angiogenesis, Vascular Endothelial Growth Factor (VEGF) is the main regulator, promoting endothelial cells proliferation, differentiation

5 Local and Regional VascularDelivery Strategiesfor Therapeutic Angiogenesisand Myogenesis

In early investigations of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), systemic intravenous delivery produced consistently poor acute and

VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohort.

No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.

Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP)

ROP: Retinopathy of prematurity; VEGF: Vascular Endothelial Growth Factor; IGF-1: Insulin-like Growth Factor-1; HIF: hypoxia-inducible factor; MAPK: mitogen-activated protein

Indirect blockade of vascular endothelial growth factor: the potential for eye disease therapy

Direct vascular endothelial growth factor (VEGF) blockade through intravitreal injections of anti- VEGF drugs has high success rates in the treatment of different neovascular